Reported Earnings • Jun 02
Third quarter 2026 earnings released: EPS: ৳3.30 (vs ৳2.81 in 3Q 2025) Third quarter 2026 results: EPS: ৳3.30 (up from ৳2.81 in 3Q 2025). Revenue: ৳10.4b (up 13% from 3Q 2025). Net income: ৳697.9m (up 17% from 3Q 2025). Profit margin: 6.7% (up from 6.4% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. 공고 • Apr 24
The ACME Laboratories Ltd. to Report Q3, 2026 Results on Apr 29, 2026 The ACME Laboratories Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026 공고 • Jan 25
The ACME Laboratories Ltd. to Report Q2, 2026 Results on Jan 28, 2026 The ACME Laboratories Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026 공고 • Nov 07
The ACME Laboratories Ltd. to Report Q1, 2026 Results on Nov 12, 2025 The ACME Laboratories Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025 공고 • Oct 29
The ACME Laboratories Ltd. announces Annual dividend, payable on January 21, 2026 The ACME Laboratories Ltd. announced Annual dividend of BDT 3.5000 per share payable on January 21, 2026, ex-date on November 19, 2025 and record date on November 18, 2025. 공고 • Oct 28
The ACME Laboratories Ltd., Annual General Meeting, Dec 22, 2025 The ACME Laboratories Ltd., Annual General Meeting, Dec 22, 2025, at 11:30 Central Asia Standard Time. 공고 • Oct 20
The ACME Laboratories Ltd. to Report Fiscal Year 2025 Results on Oct 27, 2025 The ACME Laboratories Ltd. announced that they will report fiscal year 2025 results on Oct 27, 2025 공고 • Apr 23
The ACME Laboratories Ltd. to Report Q3, 2025 Results on Apr 28, 2025 The ACME Laboratories Ltd. announced that they will report Q3, 2025 results on Apr 28, 2025 공고 • Jan 27
The ACME Laboratories Ltd. to Report Q2, 2025 Results on Jan 29, 2025 The ACME Laboratories Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025 Upcoming Dividend • Nov 14
Upcoming dividend of ৳3.50 per share Eligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 4.5%. Within top quartile of Bangladeshi dividend payers (4.5%). Higher than average of industry peers (3.6%). 공고 • Nov 11
The ACME Laboratories Ltd. to Report Q1, 2025 Results on Nov 13, 2024 The ACME Laboratories Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024 Declared Dividend • Oct 30
Dividend of ৳3.50 announced Shareholders will receive a dividend of ৳3.50. Ex-date: 21st November 2024 Payment date: 22nd January 2025 Dividend yield will be 4.6%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (29% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 12% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. 공고 • Oct 17
The ACME Laboratories Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024 The ACME Laboratories Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024 Reported Earnings • May 12
Third quarter 2024 earnings released: EPS: ৳2.75 (vs ৳2.53 in 3Q 2023) Third quarter 2024 results: EPS: ৳2.75 (up from ৳2.53 in 3Q 2023). Revenue: ৳8.00b (up 22% from 3Q 2023). Net income: ৳582.3m (up 8.6% from 3Q 2023). Profit margin: 7.3% (down from 8.1% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. 공고 • Apr 26
The ACME Laboratories Ltd. to Report Q3, 2024 Results on Apr 29, 2024 The ACME Laboratories Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024 공고 • Jan 25
The ACME Laboratories Ltd. to Report Q2, 2024 Results on Jan 30, 2024 The ACME Laboratories Ltd. announced that they will report Q2, 2024 results on Jan 30, 2024 Upcoming Dividend • Nov 18
Upcoming dividend of ৳3.30 per share at 3.5% yield Eligible shareholders must have bought the stock before 23 November 2023. Payment date: 17 January 2024. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 3.5%. Within top quartile of Bangladeshi dividend payers (3.4%). Higher than average of industry peers (2.5%). 공고 • Nov 08
The ACME Laboratories Ltd. to Report Q1, 2024 Results on Nov 13, 2023 The ACME Laboratories Ltd. announced that they will report Q1, 2024 results on Nov 13, 2023 공고 • Oct 31
The ACME Laboratories Ltd., Annual General Meeting, Dec 18, 2023 The ACME Laboratories Ltd., Annual General Meeting, Dec 18, 2023, at 05:30 Coordinated Universal Time. 공고 • Oct 30
The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023 The Board of Directors of The ACME Laboratories Ltd. has recommended 33% cash dividend for the year ended June 30, 2023. Date of AGM December 18, 2023. 공고 • Oct 19
The ACME Laboratories Ltd. to Report Fiscal Year 2023 Results on Oct 26, 2023 The ACME Laboratories Ltd. announced that they will report fiscal year 2023 results on Oct 26, 2023 Reported Earnings • May 16
Third quarter 2023 earnings released: EPS: ৳2.53 (vs ৳2.38 in 3Q 2022) Third quarter 2023 results: EPS: ৳2.53 (up from ৳2.38 in 3Q 2022). Revenue: ৳6.59b (up 8.8% from 3Q 2022). Net income: ৳536.3m (up 6.5% from 3Q 2022). Profit margin: 8.1% (down from 8.3% in 3Q 2022). The decrease in margin was driven by higher expenses. Upcoming Dividend • Nov 16
Upcoming dividend of ৳3.00 per share Eligible shareholders must have bought the stock before 21 November 2022. Payment date: 19 January 2023. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%). 공고 • Oct 28
The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022 The Board of Directors of The ACME Laboratories Ltd. has recommended 30% cash dividend for the year ended June 30, 2022. Date of AGM: December 20, 2022. Reported Earnings • May 26
Third quarter 2022 earnings released: EPS: ৳2.38 (vs ৳1.84 in 3Q 2021) Third quarter 2022 results: EPS: ৳2.38 (up from ৳1.84 in 3Q 2021). Revenue: ৳6.05b (up 16% from 3Q 2021). Net income: ৳503.7m (up 29% from 3Q 2021). Profit margin: 8.3% (up from 7.5% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year. Reported Earnings • Feb 05
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: EPS: ৳2.40 (up from ৳1.78 in 2Q 2021). Revenue: ৳5.67b (up 13% from 2Q 2021). Net income: ৳507.1m (up 35% from 2Q 2021). Profit margin: 8.9% (up from 7.5% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • Nov 14
Upcoming dividend of ৳2.50 per share Eligible shareholders must have bought the stock before 21 November 2021. Payment date: 25 January 2022. Trailing yield: 2.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%). Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 16% share price gain to ৳108, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 36% over the past three years. Valuation Update With 7 Day Price Move • Aug 09
Investor sentiment improved over the past week After last week's 15% share price gain to ৳88.10, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 13% over the past three years. Reported Earnings • Apr 30
Third quarter 2021 earnings released: EPS ৳1.84 (vs ৳1.68 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ৳5.23b (up 9.8% from 3Q 2020). Net income: ৳390.2m (up 10% from 3Q 2020). Profit margin: 7.5% (up from 7.4% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 22
New 90-day low: ৳67.60 The company is down 1.0% from its price of ৳68.00 on 24 November 2020. The Bangladeshi market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 18% over the same period. Reported Earnings • Jan 28
Second quarter 2021 earnings released: EPS ৳1.78 (vs ৳1.77 in 2Q 2020) The company reported a mediocre second quarter result with weaker profit margins, although earnings were flat and revenues improved. Second quarter 2021 results: Revenue: ৳5.02b (up 7.7% from 2Q 2020). Net income: ৳377.1m (flat on 2Q 2020). Profit margin: 7.5% (down from 8.0% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Dec 28
New 90-day high: ৳75.00 The company is up 3.0% from its price of ৳72.70 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Is New 90 Day High Low • Nov 13
New 90-day low: ৳68.00 The company is down 1.0% from its price of ৳68.90 on 13 August 2020. The Bangladeshi market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. 공고 • Oct 08
The ACME Laboratories Ltd. to Report Fiscal Year 2020 Results on Oct 14, 2020 The ACME Laboratories Ltd. announced that they will report fiscal year 2020 results on Oct 14, 2020